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Abstract
Background: The extracellular deposition of aggregated amyloid b-protein is a neuropathological manifestation of
Alzheimer disease and Down syndrome. The Amyloid b-protein is derived from a group of larger differentially
spliced proteins, the amyloid protein precursors (APP). Data suggests that the level of APP gene expression could
contribute to the pathological processes leading to amyloid depositions.
Findings: The 5’ untranslated region (UTR) of the APP gene, encompassing 147 base pairs between the
transcriptional (+1) and the translational start site, was examined for its role in APP expression. Deletions close to
the transcriptional start site reduced expression from the APP promoter in part by transcriptional mechanisms.
However, deletions between position +50 and +104 had no effect on transcriptional activity while significantly
reducing overall expression from the promoter. A nuclear factor-binding domain designated as DAPB was
identified between position +72 and +115 of the 5’-APP-UTR. The binding-recognition sequence was localized
between position +96 and +105. The same mutations that eliminated factor-binding also reduced expression from
the APP promoter while having no effect on in vitro transcription or the RNA levels transcribed from transfected
constructs.
Conclusions: A nuclear factor-binding domain designated as DAPB was identified in the 5’-UTR of the APP gene.
Elimination of factor-binding correlated with an overall decline in expression from the APP promoter while in vitro
transcription and the total amount of in vivo transcribed RNA remained unaffected. This suggests that the binding-
factor may have a function in post-transcriptional regulation, including nuclear export of mRNA.
Background
A neuropathological manifestation of Alzheimer disease
and Down syndrome is the extracellular deposition of
aggregated amyloid b-protein [1-3]. The Amyloid b-pro-
tein is derived from a group of larger differentially
spliced proteins, the amyloid protein precursors (APP)
[4]. There are three copies of the APP gene in Down
syndrome and the level of APP transcript in the brains
of afflicted individuals is increased about 4.5-fold [5]. A
chimeric mouse model of Down syndrome shows
increased APP transcription associated with cholinergic
neuron degeneration [6]. Promoter mutations that
increase the expression of APP are associated with the
development of Alzheimer disease and a duplication of
the APP gene locus causes autosomal dominant early-
onset Alzheimer disease [7,8]. These observations sug-
gest that the level of expression of the APP gene could
contribute to the pathological processes leading to amy-
loid depositions. The 5’-untranslated region (UTR) was
here examined for its role in APP expression.
Results and discussion
Deleting 5’-APP-UTR sequences between position +10
and +104 decreases expression from the APP promoter
Four incremental internal deletions within 5’-APP-UTR
construct APP [147], designated as D [10], D [30],
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D[50], and D [70] were analyzed by transient transfec-
tion (Fig. 1B and 1C). The deletions resulted in stepwise
reductions of CAT activity from 48% (D [70]) to 18% (D
[10]) of the wild type value (Fig. 2A, columns 1-5).
The deletion constructs were further analyzed by run-
off in vitro transcription. The constructs with deletions
in the 5’-APP-UTR region resulted in run-off fragments
of correspondingly smaller size (Fig. 2B, lanes 1-6).
Transcription from deletions D [30] and D [10] was
reduced to 68% and 50% of the wild type value, respec-
tively (Fig. 2C, columns 1-6). Since the deleted
sequences in D [30] and D [10] are close to the tran-
scriptional start site, they may be considered compo-
nents of the core promoter. Downstream core promoter
sequences such as DPE [9], DCE [10] or MTE [11] that
are located within the first 35 nucleotides 3’ to the tran-
scriptional start site are often required for efficient tran-
scription. However, the downstream region of the APP
promoter does not match the consensus sequences for
any of these elements. This may imply the existence of a
non-conventional proximal downstream element in the
APP core promoter. The remaining deletions D [50] and
D [70] had no effect on in vitro transcriptional activity,
while they did diminish in vivo expression from the APP
promoter (Fig. 2A and 2C). In contrast, a 3’-deletion ter-
minating at position +104 (APP [104]) had no signifi-
cant effect on APP promoter expression (Fig. 2A-C).
A nuclear factor displays sequence specific binding to the
5’-APP-UTR
The APP sequence from position -40 to +147 was ana-
lyzed by DNase I footprinting with HeLa cell nuclear
extract (Fig. 3A). A prominent DNase I protected
domain that extended from position +72 to +115 was
designated as DAPB.
The factors that interact with the DAPB sequence
were further examined by mobility shift electrophoresis
with nuclear extract fractionated on SP-Sepharose. The
major DNA binding activity eluted in fractions 10-14
(Fig. 3B, lanes 2-6). Fractions 11 and 12 were combined
and used for further experiments. The binding complex
was effectively competed with 5- and 20-fold molar
excesses of unlabeled wild type [60-120] sequence (Fig.
3C, lanes 1-3). Transverse mutations within the [60-120]
double stranded oligonucleotide were introduced from
positions +71 to +85 (M [71-85]) and +86 to +100 (M
[86-100]). Factor-binding was not effectively competed
with a 100-fold molar excess of unlabeled M [86-100]
Figure 1 Structure of the APP promoter and the 5’ UTR. (A)
Schematic representation of the APP promoter with boxes
indicating locations of regulatory regions and the DAPB domain
discussed in the text. (B) The sequence of the 5’-APP-UTR from
position +1 to +147. The translational start site (ATG) would follow
position +147 in the native APP gene. Also shown are deletions at
position +10, +30, +50, and +70 (arrows) and pertinent nucleotide
positions as discussed in the text. Brackets show relevant restriction
sites, of which SalI is part of the plasmid polylinker region. The
sequence defining DNase I protected domain DAPB (solid lines) and
the sequence recognized by the binding factor (dotted lines) are
indicated by boxes. (C) Schematic representation of internal
deletions D [10]-D [70] within the APP [147] fragment. Deleted
sequences are indicated by dotted lines.
Figure 2 Expression from the APP promoter with deletions
within the 5’-APP-UTR. (A) Expression from the full-length APP
promoter and internal 5’-APP-UTR deletions by transient transfection
in HeLa cells. The results are presented as CAT activities relative to
the wild type APP [147] construct, which was assigned the value of
100% (column 1). Columns 2-5 show internal deletions D [70]-D [10]
within APP [147] and column 6 shows the APP [104] construct that
terminates at position +104. The results represent the average
values of at least ten separate transfections with standard deviations
(error bars). (B) Run-off in vitro transcription from promoter construct
APP [104] (lane 1), APP [147] (lane 2) and sequential deletions D
[70]-D [10] (lanes 3-6). The bracket delineates fragments transcribed
from the APP promoter. Arrows indicate the two transcripts
originating from the b-actin promoter. (C) Quantitation of
transcription reactions illustrated in B. The APP transcripts were
normalized to identical b-actin transcripts and the full-length (FL)
APP [147] construct was assigned the value of 100% (column 2).
Results represent the average of four independent experiments with
standard deviations (error bars).
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fragment (Fig. 3C, lanes 4-6), whereas the M [71-85]
fragment competed the binding with a five-fold molar
excess (Fig. 3C, lanes 7-9). Additional mobility shift
competitions with 40-fold molar excesses of successive
transverse mutations M [86-90]-M [101-105] (Fig. 3D,
lanes 4-7) showed that only M [96-100] and M [101-
105] did not compete (Fig. 3D, lanes 6-7). These results
suggest that the primary binding recognition sequence is
located between position +96 and +105.
Expression from the APP promoter is reduced in
mutations that eliminate nuclear factor-binding to DAPB
The same mutations that eliminated nuclear factor-
binding to the DAPB site also decreased expression
from the respective APP [147] promoter constructs by
transient transfection. Transverse mutation M [101-105]
resulted in a decrease to 55% of the wild type value,
whereas mutation M [96-100] decreased expression
levels to 28% (Fig. 4A). Additional mutations at position
+100 within construct M [96-100] were also investi-
gated, since the original transverse mutation (Fig. 3D)
generated an additional translational start site (ATG)
within the 5’-APP-UTR, which may have interfered with
translational activity. This additional start site was elimi-
nated by replacing the terminal T residue with either C
or A residues (Fig. 4A, column 4). Indeed, in those con-
structs the activity from the APP promoter was reduced
to only 50% of the wild type value, which was consistent
with the results obtained with the M [101-105] con-
struct (Fig. 4A, column 3) and internal deletion D [70]
(Fig. 2A, column 2). This strongly suggests that this
effect is dependent on nuclear factor-binding to the
DAPB site. None of the mutations significantly affected
in vitro transcriptional activity or the level of CAT RNA
in transfected cells (Fig. 4B,C).
The DAPB mediated reduction in APP promoter
expression in vivo is therefore likely due to post-tran-
scriptional events. Indeed, an analysis employing a com-
bination of RNA fractionation and tiling arrays
identified post-transcriptionally regulated APP expres-
sion in HeLa S3 and SK-N-AS cells [12]. Several other
studies have implicated the 5’-APP-UTR in post-tran-
scriptional gene regulation [13-18]. For example, it was
shown that APP expression is regulated by an iron
response element (IRE) and an IL-1 acute box respon-
sive domain downstream from the IRE at position +101
to +146 [13,15]. However, binding of both IRP and IL-1
to RNA occurs in the cytoplasm and would thus repre-
sent later stages of the translational process. Since the
binding of DAPB occurs on double stranded DNA with
nuclear extract, it is unclear how the binding of IRP and
IL-1 relates to the functional features of the 5’-APP-
UTR described here. It has also been demonstrated that
APP synthesis is regulated through an internal ribosome
entry site (IRES) [19]. However, this IRES is located
within the first 50 nucleotides of the 5’-APP-UTR and
therefore outside of the DAPB binding domain. In addi-
tional studies, a negative thyroid hormone response ele-
ment (nTRE) between position +80 and +96 of the 5’-
APP-UTR that functions in conjunction with an adja-
cent SP1 binding site was described [20,21]. However,
Mobility shift competition with oligonucleotides con-
taining the direct repeat TRE sequence (TRE-DR4) [22]
showed no competition with the APP [60-120] element
Figure 3 Characterization of the DAPB binding domain in the
5’-APP-UTR. (A) DNase I footprinting of a wild type APP promoter
fragment extending from position -40 including the UTR to position
+147 (lanes 1 and 6). The coding strand was 5’ end-labeled with
[32P] and the resulting fragment was digested with DNase I either in
the presence (+) or absence (-) of nuclear extract. Brackets delineate
the position of DNase I protected domain DAPB from position +72
to +115 as discussed in the text. (B) Mobility shift electrophoresis
with elution fractions from SP ion exchange chromatography of
whole HeLa cell nuclear extract and a [32P] 5’ end-labeled double
stranded oligonucleotide containing the 5’-APP-UTR sequence from
position +60 to +120 [60-120]. The binding complex eluted
predominantly in fractions 11-13 (lanes 3-5). The binding complex
(b) and the free oligonucleotide (f) are indicated by brackets
throughout the figure. (C) Mobility shift competition with the 5’-
APP-UTR fragment [60-120] as a labeled probe: Mobility shift without
competitor (lane 1); mobility shift with a 5-fold (lane 2) and 20-fold
(lane 3) molar excess of unlabeled wild type [60-120] sequence;
competition with 5-fold (lane 4), 20-fold (lane 5), and 100-fold (lane
6) excess of unlabeled oligonucleotide containing transverse
mutations from position +86 to +100 (M [86-100]) within the [60-
120] fragment (lower panel); competition with a 5-fold (lane 7), 20-
fold (lane 8), and 100-fold (lane 9) excess of unlabeled
oligonucleotide containing transverse mutations from position +71
to +85 (M [81-85]). (D) Mobility shift competition with the [60-120]
fragment as a labeled probe (lane 1). Self-competition with a 10-
fold (lane 2) and 40-fold (lane 3) excess of wild type [60-120]
sequence and competition with a 40-fold unlabeled excess of
mutations M [86-90] (lane 4), M [91-95] (lane 5), M [96-100] (lane 6),
M [101-105] (lane 7), and M [86-100] (lane 8).
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for DAPB binding (not shown). Furthermore, the trans-
verse mutations that eliminate DAPB complex forma-
tion on the [60-120] fragment are actually located
outside the postulated TR recognition sequence and the
SP1 binding site. The observation that DAPB binding
was non-specifically competed by RNA (not shown) may
suggest a role in nuclear export of nascent mRNA.
Conclusion
The 5’-APP-UTR was analyzed for its effect on promo-
ter expression by transient transfection. Deletions close
to the transcriptional start site reduced expression from
the APP promoter in part by transcriptional mechan-
isms. Deletions between position +104 and +50 had no
effect on transcriptional activity while significantly redu-
cing overall expression from the promoter. A nuclear
factor-binding domain designated as DAPB from posi-
tion +72 to +115 within the 5’-APP-UTR was identified
with a recognition sequence located between position
+96 and +105. The same mutations that eliminated fac-
tor-binding also reduced expression from the APP pro-
moter while having no effect on in vitro transcription or
RNA levels transcribed from transfected constructs.
These results suggest that the nuclear binding-factor
exert its effect through post-transcriptional mechanism.
The nuclear localization of the binding factor and its
affinity for RNA may suggest a function in RNA trans-
port. A review of the literature of related studies sug-
gested that the DAPB binding-factor is distinct from
those previously described.
Materials and methods
Cell cultures, promoter constructs, and enzyme assays
Cell cultures, transient transfections, enzyme assays, and
oligonucleotide preparations were carried out as pre-
viously described [23,24].
Plasmid pCAT2bGAL [25] contains the bacterial genes
CAT and LacZ, which are both transcribed in the same
direction. The LacZ gene is transcribed from the b-actin
promoter and serves as an internal control for experi-
mental variations. The polycloning site on the 5’-end of
the CAT transcriptional unit was the recipient for the
various APP promoter constructs. The 5’-end of the
full-length APP promoter (APP [147]) construct
extended from position -488 upstream from the tran-
scriptional start site (+1)[24]. This upstream promoter
region contains all nuclear factor-binding sites relevant
for efficient APP expression (Fig. 1A). The 3’-end
extended to position +147, which in the endogenous
APP gene transcript would have been followed by the
translational start site (Fig. 1B). Mutations and deletions
within wild type APP [147] were generated by in vitro
mutagenesis [26,27].
Figure 4 Expression from the APP promoter with mutations
within the 5’-APP-UTR. (A) Transient transfection in HeLa cells. The
activities of consecutive 5-base-pair block mutations M [106-110]-M
[86-90](columns 2-5) are presented as CAT activities relative to the
wild type APP [147] construct (column 1), which was assigned the
value of 100%. In addition to the original M [96-100] mutation
(column 4, *) [see Fig. 3D for sequence], the activities of two
additional mutations (column 4, ** and ***) that removed the ATG
sequence were investigated. The results represent the average
values of at least ten separate transfections with standard deviations
(error bars). (B) Run-off in vitro transcription in HeLa cell nuclear
extract with the same designations as in A. (C) CAT RNA levels in
HeLa cells transfected with constructs APP [147] WT (column 1), M
[101-105] (column 2), and M [96-100] (column 3) were determined
by quantitative RT-PCR. The wild type APP [147] construct (column
1) was assigned the value of 100% and the results represent the
average of four independent experiments with standard deviations
(error bars).
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Nuclear extracts, mobility shift electrophoresis, and
DNase I footprinting
Nuclear extracts were prepared from HeLa cells grown
in suspension to a density of 5-8 × 105 cells/ml [23,24].
The final protein concentration in extracts was 10-15
mg/ml in buffer D [23,24]. For fractionation, a 10 ml
SP-Sepharose Fast Flow column (GE Healthcare) was
equilibrated with buffer D. Ten ml of nuclear extract
was loaded on the column, washed with 15 ml of buffer
D, and eluted with a 50 ml linear gradient of 200 mM-
700 mM KCl in buffer D. Fractions of 2 ml were col-
lected and analyzed by mobility shift electrophoresis.
For mobility shift electrophoresis, binding reactions
were assembled in a total reaction volume of 16 μl and
processed as described [23]. In competition assays,
labeled and unlabeled oligonucleotides were premixed at
indicated molar ratios before adding them to the bind-
ing reaction.
DNase I footprinting was conducted on APP DNA
fragments extending from position -40 to +147. The frag-
ments were amplified by PCR with the [32P] end-labeled
reverse primer complementary to the 5’-APP-UTR from
position +142 to +113 and unlabeled forward primer
from position -40 to -29 [24]. The resulting double
stranded DNA fragment was purified by polyacrylamide
gel electrophoresis in 0.5 × TBE. Binding reactions were
preincubated with 8 μl of HeLa cell nuclear extract and
50 × 103 cpm of labeled fragment under the same condi-
tions as described above for mobility shift electrophor-
esis, except that the total reaction volume was adjusted
to 32 μl, and processed as described [23].
Run-off in vitro transcription
Plasmid pCAT2bGAL containing the wild type or
mutated APP [147] constructs were digested with restric-
tion enzymes EcoRI and Acc65I. In vitro transcription
reactions were assembled in a volume of 8 μl containing
2.5 μl of nuclear extract, 0.5 μl (1 μg) of plasmid tem-
plate, and 5 μl of a buffer containing 40 mM Hepes, pH
7.6, 75 mM KCl, 2 mM MgSO4, 0.1 mM EDTA, 1 mM
DTT, and 10% glycerol. Thereafter, 0.5 μl of 10 mM
GTP, 10 mM CTP, 3.3 mM ATP, 3 mM UTP and 0.3-0.7
μl (106 cpm) of a-[32P]-UTP (PerkinElmer) was added
and reactions were incubated at 30°C for 30 min. Tran-
scribed RNA was purified with the RNeasy (Qiagen)
RNA isolation kit.
Quantitative RT-PCR of RNA from transfected cells
Total RNA was prepared from transfected cells with the
RNeasy Mini kit, digested with 10 units of RNase free
DNase I (Roche), and repurified. One μl of purified RNA
(0.3-0.6 μg) was combined in 10 μl annealing buffer con-
taining 300 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA
with 10 pmol each of primers Gal-R (5’-GGTTACG-
TTGGTGTAGATGGGCG) complementary to the
LacZ transcript, and CAT-R (5’-TGAGCATTCAT-
CAGGCGGGC) complementary to the CAT transcript.
The solution was heated to 99°C for 5 minutes, incubated
at 61°C for 5 min, at 57°C for 10 min, and at 48°C for
5 min. To each annealing mixture was added 40 μl of a
reverse transcriptase reaction mixture containing 12.5
mM Tris, pH 8.0, 10 mM MgCl2, 12.5 mM DTT, 1.25
mM each of the dNTPs, 20 units of AMV reverse tran-
scriptase (CHIMERx), and 10 units of RNasin (Invitro-
gen). The reaction was continued at 48°C for 90 min.
PCR amplification of 4 μl aliquots of the reverse tran-
scription reaction products was assembled in 40 μl of Mg
+ PCR buffer (Roche) supplemented with 0.2 mM of
each dNTP, 0.4 pmol each of 5’ end-labeled (50-100 ×
103 cpm) CAT-R, Gal-R, unlabeled CAT-F (5’-TTTCAG-
GAGCTAAGGAAGCTAAAATGGAG) and Gal-F
(5’-CTGAGCCGCGATATTGCCCAG) primers. Amplifi-
cation was carried out for 18 cycles. PCR products were
separated on 5% polyacrylamide gels. The amount of
CAT RT-PCR product was normalized to the amount of
LacZ RT-PCR product. To establish that the RT-PCR
procedure was quantitative, different amounts of RNA
and different numbers of PCR cycles were used. Lack of
plasmid contamination in RNA preparations was con-
firmed by amplifying aliquots of reverse transcription
reaction mixture prior to reverse transcription.
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